Overview

Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics

Status:
Completed

Trial end date:
2006-08-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetics of a single dose of daptomycin in patients aged 2-17 years old who have a suspected or proven gram-positive infection for which they are receiving standard antibiotic therapy. The tolerability of a single dose of daptomycin in these patients will also be assessed.

Phase:

Phase 1

Details

Lead Sponsor:

Cubist Pharmaceuticals LLC

Treatments:

Anti-Bacterial Agents
Daptomycin